litlas
ログインアカウント作成

M. Dror Michaelson

1993–2025 年に発表

76
論文数
25,799
被引用数
59
h 指数
74
i10 指数

被引用数

M. Dror Michaelson の年別被引用数1956 年: 被引用 2 件1991 年: 被引用 1 件1994 年: 被引用 2 件1995 年: 被引用 11 件1996 年: 被引用 9 件1997 年: 被引用 20 件1998 年: 被引用 10 件1999 年: 被引用 12 件2000 年: 被引用 12 件2001 年: 被引用 10 件2002 年: 被引用 6 件2003 年: 被引用 1 件2004 年: 被引用 7 件2005 年: 被引用 13 件2006 年: 被引用 85 件2007 年: 被引用 211 件2008 年: 被引用 236 件2009 年: 被引用 321 件2010 年: 被引用 292 件2011 年: 被引用 246 件2012 年: 被引用 190 件2013 年: 被引用 220 件2014 年: 被引用 171 件2015 年: 被引用 155 件2016 年: 被引用 158 件2017 年: 被引用 169 件2018 年: 被引用 180 件2019 年: 被引用 614 件2020 年: 被引用 628 件2021 年: 被引用 536 件2022 年: 被引用 402 件2023 年: 被引用 375 件2024 年: 被引用 557 件2025 年: 被引用 250 件2026 年: 被引用 9 件1957〜1990 年は被引用が無いため表示していません1992〜1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,034 件、この内訳の 27.5%中国: 引用元論文 668 件、この内訳の 9%イタリア: 引用元論文 487 件、この内訳の 6.6%イギリス: 引用元論文 454 件、この内訳の 6.1%フランス: 引用元論文 428 件、この内訳の 5.8%カナダ: 引用元論文 339 件、この内訳の 4.6%ドイツ: 引用元論文 339 件、この内訳の 4.6%日本: 引用元論文 268 件、この内訳の 3.6%スペイン: 引用元論文 250 件、この内訳の 3.4%オランダ: 引用元論文 206 件、この内訳の 2.8%オーストラリア: 引用元論文 149 件、この内訳の 2%スイス: 引用元論文 130 件、この内訳の 1.7%
0%27.5%その他 22.3%

機関

分野

  • Medicine71.3%
  • Biochemistry, Genetics and Molecular Biology21.1%
  • Immunology and Microbiology2.7%
  • Neuroscience1.4%
  • Computer Science0.7%
  • Engineering0.6%
  • その他2.2%

トピック

  • Renal cell carcinoma treatment14.7%
  • Renal and related cancers4.7%
  • Bladder and Urothelial Cancer Treatments4.1%
  • Cancer Immunotherapy and Biomarkers3.8%
  • Cancer Genomics and Diagnostics3.8%
  • Angiogenesis and VEGF in Cancer3.4%
  • その他65.5%

共著者

全論文

検索で開く
  1. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    著者: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Payal Kapur, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2022 被引用: 655

  2. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

    著者: Robert J. Motzer, Thomas E. Hutson, Hilary Glen, M. Dror Michaelson, Ana M. Molina, Timothy Eisen, Jacek Jassem, Jakub Żołnierek, Jose Pablo Maroto, Begoña Mellado, Bohuslav Melichar, Jiří Tomášek, Alton B. Kremer, Hanjoo Kim, Karen Wood, Corina E. Dutcus, James Larkin - The Lancet Oncology 2015 被引用: 943

  3. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    著者: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin - New England Journal of Medicine 2007 被引用: 5,756

  4. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

    著者: Pier Vitale Nuzzo, Jacob E. Berchuck, Keegan Korthauer, Sándor Spisák, Amin H. Nassar, Sarah Abou Alaiwi, Ankur Chakravarthy, Shu Yi Shen, Ziad Bakouny, Francesco Boccardo, John A. Steinharter, Gabrielle Bouchard, Catherine Curran, Wenting Pan, Sylvan C. Baca, Ji-Heui Seo, Gwo‐Shu Mary Lee, M. Dror Michaelson, Steven L. Chang, Sushrut S. Waikar, Guru Sonpavde, Rafael A. Irizarry, Mark M. Pomerantz, Daniel D. De Carvalho, Toni K. Choueiri, Matthew L. Freedman - Nature Medicine 2020 被引用: 292

  5. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

    著者: Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch - Nature Medicine 2021 被引用: 294

  6. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

    著者: Alexandre R. Zlotta, Leslie Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil Fleshner, Girish S. Kulkarni, Michael A.S. Jewett, Robert G. Bristow, Charles Catton, Alejandro Berlín, Srikala S. Sridhar, Anne Schuckman, Adam S. Feldman, Matthew Wszolek, Douglas M. Dahl, Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, David T. Miyamoto, Anthony L. Zietman, William U. Shipley, Peter Chung, Siamak Daneshmand, Jason A. Efstathiou - The Lancet Oncology 2023 被引用: 245

  7. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma

    著者: Bradley A. McGregor, Guru Sonpavde, Lucia Kwak, Meredith M. Regan, Xīn Gào, H. Hvidsten, Charlene Mantia, Xiao X. Wei, J.E. Berchuck, Stephanie Berg, Praful Ravi, M. Dror Michaelson, Toni K. Choueiri, Joaquim Bellmunt - Annals of Oncology 2023 被引用: 86

  8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

    著者: Nicholas J. Giacalone, William U. Shipley, R.H. Clayman, Andrzej Niemierko, Michael Drumm, Niall M. Heney, M. Dror Michaelson, Richard J. Lee, Philip J. Saylor, Matthew Wszolek, Adam S. Feldman, Douglas M. Dahl, Anthony L. Zietman, Jason A. Efstathiou - European Urology 2017 被引用: 400

  9. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

    著者: Toni K. Choueiri, David F. McDermott, Jaime R. Merchan, Todd M. Bauer, Robert A. Figlin, Elisabeth I. Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'souza, Zhao Song, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi - The Lancet Oncology 2023 被引用: 98

  10. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    著者: Brian I. Rini, Bernard Escudier, Piotr Tomczak, А. Д. Каприн, Cezary Szczylik, Thomas E. Hutson, M. Dror Michaelson, В. А. Горбунова, Martin Gore, И. Г. Русаков, Sylvie Négrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J. Motzer - The Lancet 2011 被引用: 1,849

  11. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 被引用: 2,189

  12. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    著者: Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Daniel J. George, Michael J. Morris - Journal of Clinical Oncology 2017 被引用: 715

  13. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

    著者: Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel J. George, Michael J. Morris - European Journal of Cancer 2018 被引用: 400

  14. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    著者: Robert J. Motzer, Bernard Escudier, Piotr Tomczak, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Stéphane Oudard, Martin Gore, Jamal Tarazi, Subramanian Hariharan, Connie Chen, Brad Rosbrook, Sinil Kim, Brian I. Rini - The Lancet Oncology 2013 被引用: 745

  15. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024

    著者: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, H.P. Bagshaw, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew J. Gunn, Naomi B. Haas, Michael P. Johnson, Payal Kapur, Jennifer King, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Randy F. Sweis, Matthew R. Zibelman, Ryan Schonfeld, MaryElizabeth Stein, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 被引用: 166

  16. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

    著者: Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon J. Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Christos E. Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley G. Somer, Jeffrey A. Sosman, Mary A. Dwyer, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2020 被引用: 259

  17. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

    著者: David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albigès, Neeraj Agarwal, Thai H. Ho, Jiaxi Song, Jean‐Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta K. Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, Sabina Signoretti - Clinical Cancer Research 2016 被引用: 228

  18. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

    著者: Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole, Charles G. Drake, Sabina Signoretti, Mahmut Akgül, Nicholas Baniak, Elsa M. Li-Ning, Matthew B. Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Z. Kaimakliotis, Yasser Ged, Phillip M. Pierorazio, E. Jason Abel, Mehmet Asım Bilen, Kenneth Ogan, Helen Moon, Krishna Ramaswamy, Eric A. Singer, Tina Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E. Delacroix, Mark J. Waples, Andrew James, Peng Wang, Toni K. Choueiri, M. Dror Michaelson, Anil Kapoor, Daniel Y.C. Heng, Brian Shuch, Bradley C. Leibovich, Primo N. Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert G. Uzzo, Gennady Bratslavsky, Naomi B. Haas, Michael A. Carducci - The Lancet Oncology 2024 被引用: 82

  19. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

    著者: Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri - European Journal of Cancer 2023 被引用: 27

  20. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson - JAMA 2006 被引用: 1,228

  21. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

    著者: Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit Jain, Mayer Fishman - European Urology 2021 被引用: 83

  22. Kidney Cancer

    著者: Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis Levine, Kim Margolin, M. Dror Michaelson, Thomas Olencki, Роберто Пили, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang - Journal of the National Comprehensive Cancer Network 2009 被引用: 470

  23. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, Brian I. Rini - Journal of Clinical Oncology 2005 被引用: 1,632

  24. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam B. Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven Hancock, Michael R. Harrison, Won Kim, Christos E. Kyriakopoulos, Chad A. LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey A. Sosman, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 被引用: 580